Shots:
- AbbVie reported pooled analysis and long-term integrated analysis of the P-lll RESONATE-2 and ILLUMINATE study evaluating Imbruvica as 1L treatment of high-risk patients with CLL. The data is presented at ASH 2020
- Results from an integrated analysis of two clinical trials ~6.5 yrs. of long-term follow-up demonstrate similar PFS and ORR in patients with/ out high-risk genomic features
- A pooled analysis across four clinical trials with ~8yrs. of follow-up result (RESONATE-2, iLLUMINATE, E1912), and PCYC-1122e study showed sustained, long-term efficacy with high 4-year PFS rates in high-risk CLL patients. Additionally, real-world data indicate low biomarker testing rates for these patients
Click here to read full press release/ article | Ref: PRNewswire | Image: Seeking Alpha
The post AbbVie Reports Results of Imbruvica (ibrutinib) in Two P-III Studies as 1L Treatment for Chronic Lymphocytic Leukemia first appeared on PharmaShots.
